| NCT ID | NCT05837663 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Lung Transplantation |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2023-11-01 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
Eligibility Criteria
Inclusion Criteria: Adult, Older adult Exclusion Criteria: Patients will be excluded from the study if they decline participation Are unable to give informed consent. Recipients of multiple organs, cancer patients and pregnant women
Contact & Investigator
Philip F Halloran, MD PhD
PRINCIPAL INVESTIGATOR
Alberta Transplant Applied Genomics Centre, University of Alberta
Frequently Asked Questions
Who can join the NCT05837663 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05837663 currently recruiting?
Yes, NCT05837663 is actively recruiting participants. Contact the research team at konrad@ualberta.ca for enrollment information.
Where is the NCT05837663 trial being conducted?
This trial is being conducted at Phoenix, United States, Gainesville, United States, Jacksonville, United States, Tampa, United States and 11 additional locations.
Who is sponsoring the NCT05837663 clinical trial?
NCT05837663 is sponsored by University of Alberta. The principal investigator is Philip F Halloran, MD PhD at Alberta Transplant Applied Genomics Centre, University of Alberta. The trial plans to enroll 600 participants.